Duke’s Poliovirus Therapy Shows Survival Benefit in Early Patients

Contact: Sarah Avery Phone: 919-660-1306 Email: sarah.avery@duke.edu https://www.dukehealth.org ASCO Abstract #2061 FOR IMMEDIATE RELEASE on Monday, June 6, 2016  DURHAM, N.C. – An early group of patients who received a modified form of the poliovirus to treat recurrent glioblastoma brain tumors showed survival improvement over historical controls, according to researchers at the Preston Robert Tisch Brain Tumor Center at Duke Health. The findings, which have not been peer reviewed, were presented at the American Society of Clinical Oncology annual meeting in Chicago (ASCO abstract #2061).  “At the first five dose levels used in the study, infusion of the modified poliovirus therapy appears to have had about a two-month survival advantage when compared to similar, non-study patients treated at our clinic,” said Annick Desjardins, M.D., associate professor of neurology at Duke and the lead author on the abstract. “Notably, a higher proportion of poliovirus patients were alive at 24 and 36 months.” The poliovirus, which has been modified to eliminate any harmful effects, is attracted to certain receptors that are in abundance on cancer cells. The modified virus homes in on tumor cells, infecting them and igniting an additional immune response. Desjardins and colleagues reported results of the first 15 patients in the phase one study. Among this early group, the dosage of the therapy was escalated on the premise that increasing the amount ...
Source: DukeHealth.org: Duke Health Features - Category: Pediatrics Tags: Duke Medicine Source Type: news

Related Links:

alho Giovanna B. Longato Glioblastoma (GBM) is the most frequent and highest–grade brain tumor in adults. The prognosis is still poor despite the use of combined therapy involving maximal surgical resection, radiotherapy, and chemotherapy. The development of more efficient drugs without noticeable side effects is urgent. Coronarin D is a diterpene obtained from the rhizome extract of Hedychium coronarium, classified as a labdane with several biological activities, principally anticancer potential. The aim of the present study was to determine the anti–cancer properties of Coronarin D in the gliobl...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Glioblastoma multiform (GBM), a malignant brain tumour, has a very often poor prognosis. The therapeutic approach is represented by surgery followed by radiotherapy and chemotherapy. Hypoxia is a factor that c...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Case report Source Type: research
Authors: Xu CH, Xiao LM, Zeng EM, Chen LK, Zheng SY, Li DH, Liu Y Abstract Gliomas are aggressive type of brain tumors and cause significant human mortality world over. The frequent relapses, development of drug resistance, the adverse effects of the chemotherapy and dearth of the therapeutic targets form the major hurdles in glioma treatment. Several studies suggest that microRNAs (miRs) are involved in the development and progression of different cancers. Herein, the therapeutic potential of miR-181 was explored in human glioma cells. The results showed that miR-181 is significantly downregulated in human glioma ...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Daria Riva Neurofibromatosis type-1 (NF1) is a monogenic tumor-predisposition syndrome creating a wide variety of cognitive and behavioral abnormalities, such as decrease in cognitive functioning, deficits in visuospatial processing, attention, and social functioning. NF1 patients are at risk to develop neurofibromas and other tumors, such as optic pathway gliomas and other tumors of the central nervous system. Few studies have investigated the impact of an additional diagnosis of brain tumor on the cognitive outcome of children with NF1, showing unclear results and without controlling by the effect of surgery, radio-...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: 6 November 2019Source: Neuron, Volume 104, Issue 3Author(s): David H. Gutmann, Helmut KettenmannOne of the most common brain tumors in children and adults is glioma or astrocytoma. There are few effective therapies for these cancers, and patients with malignant glioma fare poorly, even after aggressive surgery, chemotherapy, and radiation. Over the past decade, it is now appreciated that these tumors are composed of numerous distinct neoplastic and non-neoplastic cell populations, which could each influence overall tumor biology and response to therapy. Among these noncancerous cell types, monocytes (micr...
Source: Neuron - Category: Neuroscience Source Type: research
Purpose of review The current treatment of gliomas dovetails results of decades-old clinical trials with modern trends in chemotherapy. Molecular characterization now plays a pivotal role, and IDH mutations are key characteristics and the subject of active debate. IDH-mutant tumors produce the ‘onco-metabolite’, 2-hydroxyglutarate. Metabolic changes have become central to the understanding of tumor biology, and tumors display a fundamental metabolic change called the Warburg Effect. The Warburg Effect represents a preference for glycolysis, as opposed to oxidative phosphorylation. The present review details t...
Source: Current Opinion in Neurology - Category: Neurology Tags: NEOPLASMS: Edited by Antonio Omuro Source Type: research
l Sunit Das Glioblastoma (GBM) is the most common high-grade primary brain tumor in adults. Standard multi-modality treatment of glioblastoma with surgery, temozolomide chemotherapy, and radiation results in transient tumor control but inevitably gives way to disease progression. The need for additional therapeutic avenues for patients with GBM led to interest in anti-angiogenic therapies, and in particular, bevacizumab. We sought to determine the efficacy of bevacizumab as a treatment for newly diagnosed GBM. We conducted a literature search using the PubMed database and Google Scholar to identify randomized control...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Remke Gough Medulloblastoma is the most common malignant brain tumor in children and represents 20% of all pediatric central nervous system neoplasms. While advances in surgery, radiation and chemotherapy have improved overall survival, the lifelong sequelae of these treatments represent a major health care burden and have led to ongoing efforts to find effective targeted treatments. There is a well-recognized male bias in medulloblastoma diagnosis, although the mechanism remains unknown. Herein, we identify a sex-specific role for the transcription factor Signal Transducer and Activator of Transcription 3 (STAT3)...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Brief Report Source Type: research
In pediatric brain tumors, the intensification of chemotherapy has allowed for a reduction in radiotherapy (RT) volume to an involved field approach, particularly in patients with medulloblastoma. For patients with low-grade gliomas, the trend has remained to delay RT with chemotherapy; however, when RT is used, typically smaller clinical target volume margins are used. For patients with extracranial tumors, intensive chemotherapy to address systemic disease with local control is considered standard. Proton beam therapy shows significant promise in addressing both short-term and long-term toxicities in both central nervous...
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Source Type: research
Conclusions. In summary, RES529, the first dual TORC1/TORC2 dissociative inhibitor, lacking affinity for ABCB1/ABCG2 and having good brain penetration, was active in GBM preclinical/murine models giving credence to its use in clinical trial for patients with GBM treated in association with anti-angiogenetic compounds.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Avastin | Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Chemotherapy | Health | History of Medicine | Neurology | Pediatrics | Study